GLP1R and type 2 diabetes mellitus: in June 2019, the UK Medicines and Healthcare Products Regulatory Agency reported that DKA may occur in type 2 diabetes patients receiving combined GLP1 receptor agonists and insulin therapies when insulin is abruptly reduced or discontinued.[10]